Nautilus Biotechnology: Karen Akinsanya

Proteomics firm Nautilus Biotechnology has appointed Karen Akinsanya to its board of directors. Akinsanya is currently president of R&D for therapeutics at Schrödinger. Prior to joining Schrödinger, she held positions of increasing responsibility over more than a decade at Merck Research Laboratories, including as associate director of clinical pharmacology; executive director and therapeutic area lead in discovery preclinical and early development; and associate VP of business development and licensing. She holds a bachelor's degree in biochemistry from Queen Mary University of London and a PhD in endocrine physiology from the Royal Postgraduate Medical School at Imperial College London.